A Phase 3 Open Label, Randomized, Multicenter Study of Treatment of Physician’s Choice (TPC) in Patients with Metastatic Breast Cancer Who have Stable Brain Metastases and have been Previously Treated with an Anthracycline, a Taxane, and Capecitabine.